Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Cumberland's Ifetroban Shows Potential to Limit Metastasis
CPIX reports positive Phase 2a results for Ifetroban, showing a favorable safety profile and promising early signs of reducing cancer metastasis in high-risk patients.
Cumberland Posts Loss in Q1 Amid $100M Apotex Deal Plan
CPIX posts a wider y//y loss in Q1, as it unveils a $100-million Apotex deal and sharpens focus on orphan drug development.
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2026 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2026 Earnings Call Transcript
Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts Sales
CPIX's Q4 revenues jump 31%, while loss narrows year over year as sales of Vibativ, Sancuso and new product Talicia boosted its performance.
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2025 Earnings Call Prepared Remarks Transcript
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2025 Earnings Call Prepared Remarks Transcript
Niche Focus & Regulation Shape the Future of Healthcare Firms
CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.
Zacks Initiates Coverage of CPIX With Outperform Recommendation
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates Cumberland as "Outperform." Explore how CPIX's scalable commercial model, long-duration Talicia revenues and pipeline upside create an attractive risk-reward setup for investors.
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants A. J. Kazimi - Founder, Chairman, President & CEO John Michael Hamm - VP & CFO Todd M.
Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX ) Q1 2025 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Conference Call Participants Operator Good afternoon, and welcome to the Cumberland Pharmaceuticals First Quarter 2025 Financial Report and Company Update.
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Molly Aggas – Account Supervisor-Dalton Agency A.J. Kazimi – Chief Executive Officer Todd Anthony – Vice President-Organizational Development John Hamm – Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals Fourth Quarter 2024 Financial Report and Company Update.
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
On Tuesday, Cumberland Pharmaceuticals Inc. CPIX released topline results from its Phase 2 FIGHT DMD trial.
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
On Monday, the FDA approved Cumberland Pharmaceuticals Inc's CPIX supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product.
